AUTHORS
Yue Huang, PhD, Gang Xiao, PhD2, He Huang, MD, PhD3
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, Zhejiang, China
2 The First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, Zhejiang, China
3 The First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, Zhejiang, China
ABSTRACT
Functional exhaustion and limited persistence were major barriers to durable CAR-T-cell responses. These defects are closely linked to impaired metabolic plasticity within the immunosuppressive and nutrient-deprived tumor microenvironment (TME). Although metabolic reprogramming is known to be essential for CAR-T-cell function, the contribution of lipid metabolism to CAR-T cell exhaustion remains poorly understood. Here, we systematically characterized the lipid metabolic remodeling within the TME and identified metabolic enzyme DGAT1 as a critical CAR-T cell fate regulator.
We established an in vitro exhaustion model and performed targeted lipidomics and metabolic flux analyses in primary human CAR-T cells. Repeated tumor antigen stimulation induced accumulation of triacylglycerol (Log2FC = 1.92), free fatty acids (Log2FC = 0.9) and lipid droplets, accompanied by reduced acyl-CoA (Log2FC = -0.5) and acylcarnitine levels (Log2FC = -1.4), indicating impaired lipid utilization. Transcriptomic analysis further revealed increased enrichment of de novo lipid synthesis and storage programs in exhausted CAR-T cells. We therefore screened small-molecule inhibitors targeting enzymes, including ACC1/2, FASN, cPLA2, SCD1, and DGAT1/2, to identify therapeutic metabolic candidates. Among these targets, DGAT1 inhibition exhibited the most pronounced improvement in CAR-T cell function. Pharmacologic inhibition with DGAT1 inhibitor T863 or shRNA-mediated DGAT1 knockdown reduced CAR-T-cell exhaustion and preserved memory-like differentiation, reflected by increased CD62L+CD45RO+ proportion and reduced TIM-3, LAG-3 and PD-1 expression. At an E:T ratio of 1:1, T863-pretreated CAR-T cells exhibited enhanced cytotoxicity against Nalm-6 cells after multiple rounds of challenge. Consistent with the in vitro findings, integrated pan-cancer single-cell transcriptomic reanalysis revealed that lower DGAT1 expression correlated with improved responses to anti-PD-1/CTLA-4 immunotherapy in melanoma, suggesting DGAT1 as a potential biomarker of T-cell functional state and immunotherapy response.
To evaluate the in vivo efficacy of DGAT1 inhibition, we assessed inhibitor pretreatment and systemic combination therapy in NSG xenograft models. In a B-ALL model, T863-pretreated CAR-T cells achieved superior tumor control and prolonged survival (Median Survival: T863 47 days, DMSO 37.5 days, P<0.0001). Similar effects were observed in an osteosarcoma model. In exhaustion-prone anti-GD2 CAR-T cells, T863 pretreatment combined with intragastric administration further enhanced antitumor activity and overall survival in GD2-expressed Nalm-6 model (Median Survival: DMSO+Veh 29 days, PreT863+Veh 35 days, PreT863+T863 42days, P<0.0001).
Mechanistically, DGAT1 inhibition redirected fatty acids away from triglyceride synthesis toward fatty acid oxidation. Lipidomics and 13C-palmitate tracing demonstrated increased acyl-CoA, acylcarnitine, phospholipid, and phosphatidylethanolamine synthesis with reduced neutral lipid storage. Metabolic flux analysis further showed enhanced fatty acid oxidation, mitochondrial oxidative phosphorylation, and spare respiratory capacity upon DGAT1 inhibition. Increased CPT1A expression accompanied these metabolic changes, while the CPT1A inhibitor etomoxir reversed the cytotoxicity-enhancing effect of T863, supporting a critical dependence on FAO. Furthermore, DGAT1 inhibition enhanced autophagic activity in CAR-T cells, as evidenced by increased LC3B-II/I ratio and more autophagic puncta formation. Genetic disruption of autophagy by BECN1 knockdown abolished the functional benefits of DGAT1 inhibition, demonstrating the requirement of autophagy for enhanced CAR-T-cell function. We proposed that these effects may be attributed to acyl-CoA-mediated AMPK activation and PE-facilitated LC3 lipidation during autophagosome elongation.
In conclusion, DGAT1 inhibition metabolically rewires CAR-T cells by diverting fatty acids from neutral lipid storage toward fatty acid oxidation while promoting acyl-CoA/PE-dependent autophagy. This metabolic programming preserves functional fitness and enhances antitumor efficacy, which identify DGAT1 as a promising metabolic target for next-generation CAR-T-cell therapy.
DISCLOSURES
Yue Huang, PhD: No relevant conflicts of interest to declare.